chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Memory issues - difficulty identifying, focusing, following thru; This spontaneous case was reported by a consumer and describes the occurrence of MEMORY IMPAIRMENT (Memory issues - difficulty identifying, focusing, following thru) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Food intolerance NOS (Food sensitivities).   On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-Jun-2021, the patient experienced MEMORY IMPAIRMENT (Memory issues - difficulty identifying, focusing, following thru). At the time of the report, MEMORY IMPAIRMENT (Memory issues - difficulty identifying, focusing, following thru) outcome was unknown.            No concomitant medications were reported.  No treatment information was reported.
Myalgia  fatigue  Narrative:  Per supervisor report: "received second dose COVID-19 vaccine on 4/21/2021 having symptoms of tired, achy all over."
wrong diluent used; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 16-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA771A, expiry date 31-JAN-2024) for prophylaxis.   On 15-MAY-2023, the patient received Menveo. On 15-MAY-2023, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: wrong diluent used). The outcome of the wrong solution used in drug reconstitution was unknown.   Additional Information: GSK Receipt Date: 16-May-2023  Nurse stated a patient was given a dose of Menveo that was reconstituted with sterile water instead of the liquid portion of the vaccine, which led to wrong solution used in drug reconstitution. The vaccine administration facility was the same as primary reporter. No further details provided.  The reporter consented to follow up.
runny nose; sore throat; eye itchiness; This is a spontaneous report from a contactable consumer or other non hcp (Patient).   A female patient of an unspecified age received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number and expiration date were not reported) via an unspecified route of administration on 25Feb2021 as dose 1, single for covid-19 immunization. The patient's medical history and concomitant medications were not reported. On 23Mar2021, patient experienced runny nose, sore throat and eye itchiness. Patient said her schedule appointment is at 2:00 pm today but it's 45 minutes away from here. I don't want to drive all the way there. Can you tell me if I can receive the second dose today. caller was frustrated because she is been on the call since 9:00 a.m. At the time of reporting, the outcome of the events were unknown.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 65-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 04Apr2022 at 20:00 as dose 4 (booster), single (Lot number: FS6369) at the age of 64 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history and no known allergies. Concomitant medication(s) included: CARBAMAZEPINE, start date: 01Jan2018, stop date: 24Jul2022; ROSUVASTATIN, start date: 01Jan2020; METAMUCIL [PLANTAGO OVATA]; BIOTIN; KRILL OIL; COQ10 [UBIDECARENONE]; MVI [ASCORBIC ACID; DEXPANTHENOL; ERGOCALCIFEROL; NICOTINAMIDE; PYRIDOXINE HYDROCHLORIDE; RETINOL; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; TOCOPHERYL ACETATE]; VIT D3; VIT C; CALCIUM + MAGNESIUM + ZINK; TURMERIC [CURCUMA LONGA RHIZOME]. The following information was reported: DISEASE RECURRENCE (medically significant) with onset 08Aug2022 at 09:00, outcome "recovering", described as "After Paxlovid tested neg on 30Jul22 & tested positive on 08Aug22"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (30Jul2022) Negative; (02Aug2022) positive. Therapeutic measures were taken as a result of drug ineffective, covid-19: the patient received Paxlovid (Lot number=NDC: 00069-1085-30) as COVID 19 treatment from 24Jul2022 to 29Jul2022. No treatment received for "After Paxlovid tested neg on 30Jul22 & tested positive on 08Aug22" as reported. Clinical course: After Paxlovid tested neg on 30Jul2022 & tested positive on 02Aug2022. Fever, cold, cough, tired, aches, worse then very minor 3 days of SX with Paxlovid.
Reaction occurred immediately after the shot was administered. large raised red area approximately 6 inches in circumference with itching and burning. Allergic reaction occurred above the shot and in shoulde area. Benadryl was administered a number of times as the hives came and went. Additionally, the spot would reduce with benadryl administered and then return in size as the medication wore off. This continued for about 4 days. It is now day 6 and the red spot is fading and there are no more hives.
significant immune response; Lethargy; Aches; Chills; Fever for 101; headache; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNISATION (significant immune response), LETHARGY (Lethargy), PAIN (Aches), CHILLS (Chills) and PYREXIA (Fever for 101) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 on 12-Nov-2020 and Neuropathy in 1995. Concomitant products included METHYLCELLULOSE (CITRUCEL) for Gastrointestinal disorder NOS, CALCIUM CARBONATE, COLECALCIFEROL (CALCIUM + VITAMIN D [CALCIUM CARBONATE;COLECALCIFEROL]) for Osteopenia, IPRATROPIUM for Rhinitis, FISH OIL for Routine health maintenance, ESTRADIOL for Vaginal dryness.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced IMMUNISATION (significant immune response), LETHARGY (Lethargy), PAIN (Aches), CHILLS (Chills), PYREXIA (Fever for 101) and HEADACHE (headache). The patient was treated with PARACETAMOL (TYLENOL) for Symptomatic treatment, at a dose of UNK, as necessary. On 29-Jan-2021, LETHARGY (Lethargy), PAIN (Aches), CHILLS (Chills), PYREXIA (Fever for 101) and HEADACHE (headache) had resolved. At the time of the report, IMMUNISATION (significant immune response) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 05-May-2021: Patient demographics(Height, Weight, Race, Ethnicity) provided; Past medical history(Neuropathy) provided; concomitant medications provided; stop date and outcome for events provided; treatment information provided.
THIS VACCINE WAS GIVEN TO MY SON AT 23 MONTHS, THIS VACCINE WAS HPV4 HUMAN PAPILLOMAVIRUS, QUADRIVALENT MANUFACTURER MERK AND CO.,INC. DOSE:00.50 THIS SHOULD NOT HAVE BEEN GIVEN TO MY SON ALSO ANOTHER VACCINE WAS GIVEN THAT SHOULDN'T HAVE BEEN GIVEN ONLY 2 DOSE SHOULD BE DONE THIS ONE  WOULD OF BEEN A 3RD ONE. HPV VACCINES ARE  NOT GIVE TO KIDS UNTIL THEY ARE 12 YEARS MY SON WAS 23 MONTHS. THIS IS HORRIBLE AND SHOULD NEVER HAPPENED. MY SON HAS BEEN HAVING GASTROINTESTINAL PROBLEMS SINCE HE WAS BABY AND STILL GOING, ASTHMA AND ALLLERGIES, HAD TONSILS ADNOIDS AND TUBES IN EARS. HIS SISTER HAS NO ISSUES. FACILITY HAS DISSAPPOINTED ME AND IM LOOKING FOR A LAWYER. FINDING THIS OUT NOW HURTS. SEEING GASTRO SPECIALIST
I did not have an adverse reaction to the vaccine. I tested positive with the home test for COVID-19 06/18/2022. The only symptom that I had was a scratchy throat. I had a telehealth visit with my doctor and he stated that my symptoms was to mild for the antiviral medication.
Starting 12/23/2022, at night, I went to bed not feeling great. I woke up the next day I was sick with head cold symptoms and I took an at-home COVID-19 test (12/24/2022) which came back positive. The symptoms continued until they were bad head cold symptoms. I contacted the doctor that same day and they prescribed Paxlovid. I was unable to start it until 12/26/2022 due to the holidays. Starting 12/27/2022 after starting the medicine the day before, I gradually started feeling better. I did have the side effect from the Paxlovid where the taste in my mouth was awful. The acute symptoms (bad cold symptoms) lasted until about 12/31. As of today, I am still not 100% better but I am much better than I was.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Flushed / Sweating-Mild, Additional Details: Pt starting sweating and complaint of dizziness, so I laid down on the floor and took his blood pressure which was in normal limits.  After resting for a few minutes he was able to sit up in his chair.  I monitored him for a total of 45 minutes after which he felt fine and left the pharmacy.
Numbness from the knees down, numbness from the elbows down; burning sensation in his joints; burning and tingling sensation in his face; burning and tingling sensation in his face; exhaustion; really bad headache; This is a spontaneous report from a contactable 36-year-old male consumer reported for himself. A 36-years-old male patient received bnt162b2 (BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot Number: unknown, via unspecified route, on 13May2021 (at 36-years age) as 1 st dose, single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. In May2021 the patient had experienced numbness from the knees down, numbness from the elbows down, burning sensation in his joints, burning and tingling sensation in his face. All these effects come and goes. He also experienced exhaustion and a really bad headache 1 night. He had already gone to the ER twice. The patient underwent lab tests and procedures which included several blood test, CAT Scan (computerized tomogram), EKG(Electrocardiogram) which all came back normal, and he was perfectly fine. He had consulted with his neurologist and orthopedic doctors and both had no findings for him. The outcome of the events was unknown.   Information on the lot/batch number has been requested.
Moderna COVID-19 Vaccine EUA headache in the afternoon, followed by insomnia that evening resulting only 2 hours of sleep as well as stomach cramps and stomach pain into the next day; chills the next day
pt recv vax 3NOV97 & 6NOV97 pt exp very mild rash on face w/some areas of raised redness;it was reported that for approx 3 days had a dry rash that looked like a bunch of red/purple dots;
Patient received second dose of Moderna 5/20/2021.  6/18 patient tested as part of a preprocedural exam.  Has been asymptomatic.  Vaccination lot number is not listed in the .    Lab sample is being sent for genome sequencing
joints, I'm retaining water really bad, especially on the right side, and my joints are swollen. I have to walk up and down stairs to my bedroom and it really hurts my knee and my foot and I've started to wear a knee brace sometimes. My arm hurts from my shoulder to my fingers and my back and ribs on the right are in constant pain. I have also had diarrhea since getting the shot and I usually do not have that problem.
redness @ site immed p/localized 2" circle;pt c/o itchy immed p/vax;no resp sx;19OCT98 pt dx w/cellulitis @ inj site;
This case was reported by a consumer and described the occurrence of injection site cellulitis in a child male patient who received FLULAVAL QUADRIVALENT 2018-2019 season (batch number AM5N3, expiry date unknown) for prophylaxis. On 14th November 2018, the patient received FLULAVAL QUADRIVALENT 2018-2019 season. On an unknown date, less than a month after receiving FLULAVAL QUADRIVALENT 2018-2019 season, the patient experienced injection site cellulitis. On an unknown date, the outcome of the injection site cellulitis was unknown. It was unknown if the reporter considered the injection site cellulitis to be related to FLULAVAL QUADRIVALENT 2018-2019 season. Additional details were provided as follows: This case was reported by the patient's mother. The age at the vaccination was not reported. The reporter reported that the patient developed cellulitis where the injection was given. The reporter had contacted the school where it was given, the company that gave it and the company that made it. The reporter was so upset and reported that this was a lifelong battle for them that he did not have before this vaccine. The reporter would be getting an attorney to move forward to help cover any cost in future for medical bills, hospital stays etc. if needed. This was going to cause more loss of time at work for her and possible loss of school days for the patient if it flares up again. This was so heartbreaking to know that her child was healthy before this and now had something in his body that would last a lifetime. The reporter wanted GlaxoSmithKline should look into this shot because whether or not it happens to anymore children, it should have never happened to anyone.
the patient experienced tinnitus; This is a spontaneous report from a contactable pharmacist. A 46-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on Dec2020 at single dose for covid-19 immunisation. Medical history was reported as none. There were no concomitant medications. The patient experienced tinnitus (tinnitus) on Dec2020 after receiving the vaccine. The patient went to see his doctor, but no cause for the tinnitus was identified. No treatment for the tinnitus was administered. Outcome of event was not recovered.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
This spontaneous report was received from a licensed practical nurse concerning an unspecified number of patients (ages and genders not specified) who reported that one dose of VARIVAX (Merck) and 10 doses of PROQUAD (Merck) that were improperly stored were administered to an unspecified number of patients. No adverse effects were reported. Follow up information has been received from licensed practical nurse via telephone call on 12-FEB-2015. Total number of doses administered of PROQUAD (Merck) were 20. This report refers to a 6 year old patient. On an unknown date patient was vaccinated with inappropriately stored PROQUAD (Merck) (batch/lot: lot no. K011968, expiry: 21-FEB-2016). There was no need for revaccination. The outcome of incorrect product storage and no adverse event were unknown. This is one of several cases from the same reporter. Additional information has been requested.
Pneumonia; This spontaneous report was received from a currently 64-year-old female patient who was a registered nurse referring to herself. Concurrent conditions included type 2 diabetes mellitus, allergic to oral hypoglycemic (sulfa based), allergic to fish and allergic to metformin. Historical drug included metformin. Medical history and concomitant medication were not reported.  On an unknown date, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) for prophylaxis (strength, dose, route, lot#, and expiration date were not reported).  On an unknown date (reported as years ago), the patient experienced pneumonia. The outcome of pneumonia was unknown.  The causality between pneumonia and pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was not reported.  Upon internal review, pneumonia was determined to be medically significant.
A rash that started in my left arm where the vaccine was administered. In less than 24 hours the rash had spread to my stomach, back, neck, right arm, and buttocks.  The rash was really itchy, and my skin almost looked swollen. I also had sharp pains when taking deep breaths and exhaling,  Went to see my doctor that Tuesday morning and he administered a shot of steroids in the office, and also called in a prescription for prednisone which I am still taking.  The prednisone did work thankfully. It took about 5 days before I started seeing the rash disappear.
Sore throat; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (Sore throat) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced OROPHARYNGEAL PAIN (Sore throat). At the time of the report, OROPHARYNGEAL PAIN (Sore throat) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant medication were reported. No treatment medication were reported.
On 6/3/06 pt began to look and feel ill. 06/27/06-medical records received from hospital. DC abstract documented principal DX streptococcus pneumoniae bacteremia. Additional diagnosis dysmorphic genital-patellar syndrome. Patient presented to ED with fever, lethargy, vomiting, positive blood culture on admission. Current medications included Zantac and Suprax. Temp 37.6.  TX included IV ceftazidime. PMH includes G-tube placement, bilat hearing aids.  8/1/06-received final blood culture report from Hospital. Streptococcus pneumoniae.
Throat felt constricted; A little dizziness; Weakness in his body; Had swelling of face; This spontaneous case was reported by a consumer and describes the occurrence of THROAT TIGHTNESS (Throat felt constricted), DIZZINESS (A little dizziness), ASTHENIA (Weakness in his body) and SWELLING FACE (Had swelling of face) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced THROAT TIGHTNESS (Throat felt constricted), DIZZINESS (A little dizziness), ASTHENIA (Weakness in his body) and SWELLING FACE (Had swelling of face). At the time of the report, THROAT TIGHTNESS (Throat felt constricted), DIZZINESS (A little dizziness), ASTHENIA (Weakness in his body) and SWELLING FACE (Had swelling of face) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not reported.  Treatment information was not provided.
p/vax pt became ill w/sharp burning pain in lt lower quadrant of abd, inc temp 102.4, chills, unable to get warm was placed in hosp;tx of flagyl & Cipro;began strawberry rash over most of body;
Information has been received from a physician and a nurse concerning a 14 year old female patient with no drug reactions/allergies, who on 23-OCT-2008 was vaccinated with the first dose of GARDASIL.  The physician reported that the patient fainted after receiving the GARDASIL.  The nurse reported that "the patient upon feeling weak on one side of her body, the patient did fall".  The patient recovered 15 minutes later after having the symptom. The patient sought unspecified medical attention.  Follow up information has been received from a medical assistant on 12-JAN-2009. It was reported that the patient felt faint and unable to stand on her own. The GARDASIL site of administration was the left deltoid (lot number 661046/0381X) and was given on 23-OCT-2008 at 15:42.  Additional information is not expected.
The patient came in today showing visible signs of hive like red, raised bumps on her forearms, hands, arms, thighs, and back of knees. She said within an hour of vaccine administration she immediately started feeling symptoms of redness, itching and welts all over. No breathing issues or other side effects reported. She says the bumps/hives that she showed me today are much improved from what they were.
No known adverse effects; a patient received an expired dose of VARIVAX; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions, allergies and concomitant therapies were not reported. On 18-OCT-2019, the patient was vaccinated with expired dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot # N021720, expiration date 10-AUG-2019 (strength, dose and route of administration were not provided) for prophylaxis. There were no adverse effects.
Soreness on the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Soreness on the injection site) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Allergy to vaccine (Allergic to FLU Shot, can not take any shot that contain live or killed virus).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Soreness on the injection site). At the time of the report, VACCINATION SITE PAIN (Soreness on the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provider by the reporter.  Treatment information was not provided.   Patient had first shot of Moderna COVID-19 vaccine three weeks ago .
Pt received HPV #1. Seemed fine after vaccine was given. Told to wait in the waiting room for 15 min. If pt was ok she could leave after the 15 min, grandma was told. I went to waiting room to check on pt and she started to bend over, pt passed out in my arms, pt came to 20 sec later gave pt a drink & took BP walked back to Rm, layed down, retook BP it was in normal range. Dr came in 20 min later & checked pt and she seemed fine and was sent home after 15 min later.
developed shortness of breath.  was seen in the ER and diagnosed with PE.  Only other risk factor was OCP's
Pericarditis symptoms. Relieved when patient took colchicine which is standard treatment patient was receiving for previous instance of pericarditis.
Headache, chills, red, swollen arm, hives Seen at ED 1/27/21 as became ill at work. Received IV pain med and steroid injection. Dr. not to remain off work thru 1/30/21. Hives still present at time of report on 2/2/21. Duration of sx approx one week
vasculitis; other zoster-related conditions; Information has been received from a lawyer as part of litigation and refers to a currenlty 74-years-old patient of unknown gender. The patient's concurrent conditions, medical history and concomitant therapy were not reported. On or about 01-JAN-2015, the patient was vaccinated with a dose of zoster vaccine live (ZOSTAVAX) (dose, route of administration, lot # and expiration date were not reported)  for the long-term prevention of shingles and zoster-related conditions, by a healt professional in a physician's office. Subsequently, the patient was treated by a healthcare provider for the following injuries resulting from patient's use of zoster vaccine live (ZOSTAVAX): vasculitis and other zoster-related conditions. The outcome of the events was not repoted. The reporter considered vasculitis and other zoster-related condition to be related to zoster vaccine live (ZOSTAVAX).